Home Today's Paper Most Popular Video Gallery Photo Gallery
Subscription Blog Signin Register
Logo
Tuesday, October 16, 2018 12:28:41 AM
Follow Us On: Facebook Twitter Twitter Twitter Twitter

Innovation doesn't happen by accident

By
13th-May-2018       
Comments
Share your thought
Post a comment »
Read all () »

Mark J. Alles :
But today, some question the real impact of innovation in healthcare and if it is worth it. The European Commission is currently considering modifications to the intellectual property framework in Europe, partially in response to the chronic sustainability and affordability challenges among healthcare systems. But some of these proposals likely put the healthier future we all envision at risk by stifling innovation that is critical to economic growth and improving healthcare.
There is no doubt that we face challenges in healthcare, but solutions must address these challenges while still fostering growth and progress. Too often, this debate is reduced to a single issue: the perceived high cost of medicines. However, this is a massive oversimplification of a much bigger picture. The complexities of managing healthcare expenditures in Europe while driving health gains and economic prosperity over the long term are great. In this effort, incentives must encourage innovation, not deter it.  Understanding the facts is an important start:
First, medications account for less than 15% of overall EU healthcare spending, and several recent studies refute the long-held belief that medicine costs are rising uncontrollably. A recent study on the projected impact of medicines in the UK, France, Germany, Spain and Italy shows that the net pharmaceutical expenditure is projected to rise just 1-2% over the next five years, in line with projected economic growth. These modest increases should not be blamed for long-term sustainability issues across the entire healthcare system.
Second, we must consider the role of today's intellectual property framework, which aligns appropriate incentives to drive innovation with continuing value for generations through the availability of lower-cost generic medicines when novel medicines lose their exclusivity. Of course, we need to collaborate on solutions for short-term affordability issues, and the biopharmaceutical sector has shown its willingness and ability to advance positive solutions. But we must also preserve what is working: today's incentives framework stimulates transformative research, ensures competition, and rewards innovators for investing in the challenging research required to discover new medicines.
The incentives framework in the EU has proven itself, successfully driving innovation and reducing the financial impact of diseases across many therapeutic areas. For example, in rare diseases, the Orphan Regulation was introduced precisely to spur innovation in some of the most difficult-to-treat diseases affecting small numbers of people. As a result, people with life-threatening and seriously debilitating rare diseases in Europe have benefitted from significant investment and a dramatic increase in available medicines to treat their conditions - from just 8 medicines for orphan indications 15 years ago to more than 140 medicines today.
At Celgene, more than ten years of research focused on multiple myeloma, a rare, life-threatening, blood cancer, allowed us to develop three novel medicines that have helped contribute - along with other therapies - to the doubling of the five-year survival rate for patients living with multiple myeloma.
The first of Celgene's multiple myeloma medicines will lose market exclusivity later this year, joining the medicine cabinet of generics that will continue to deliver value for society at low costs for as long as they remain necessary for the treatment of a specific disease.
Beyond offering a tested and proven framework, incentives are also responsible for encouraging investment in high-risk research that has the potential to one day cure diseases like cancer, dementia and heart disease. At Celgene, we invest nearly 40% of our revenues on average back into R&D annually. This investment is risky. In fact, we recently stopped clinical studies on a compound for Crohn's Disease, because our investigational medicine did not show enough impact on the disease to support continued clinical development in this setting. We will never recover our investment on this compound, but we took this risk because patients need new and better options. This decision and others like it are possible because we currently work within an innovation framework that rewards those successful medicines that do make a difference for patients.
Finally, we are very aware of how innovation incentives impact industrial policy, including job creation and economic investment. For instance, Celgene, a U.S.-based company, chose to establish operations in Europe 11 years ago because of the confidence created by the EU incentives environment. Without such support, Celgene may not have established operations in Europe, that brought more than 2000 jobs, significant R&D investment, and, of course, innovative medicines to patients in Europe.
The EU's decisions about the future of incentives for biopharmaceutical innovation will have broad implications. Global competition to attract investments is increasing.  Maintaining a competitive environment is critical to continue attracting investment as well as stimulating the creation of new ones. And while medical technologies have advanced over the past 30 years, reimbursement models have not. Appropriate reimbursement models can also align the right incentives and allow us to seize the opportunities that science is delivering.
All that to say, innovation doesn't happen by accident; it is the result of high-risk, long-term investment which is only possible when companies and investors are confident that they will be able to make reasonable returns if successful. The limited period of exclusivity within today's incentives framework is key to this virtuous cycle of investment. With the right incentives in place, biopharmaceutical companies can continue to invest in R&D and enable broader access to innovative medicines that can have a life-changing impact on patients and the healthier world we are creating together.

(Mark J. Alles is Chairman and CEO of Celgene).

Tariff
Add Rate

News Archive

Inside The New Nation

Editorial »

Question paper leakage continues: Incompetence is everywhere


QUESTION paper leaks have become epidemic before all public exams, university admission tests, and job recruitment tests during the current administration allegedly by some students and unscrupulous teachers along with office staffs. Detectives in recent times busted dens of criminals involved in the question leakage but the unholy nexus between ...

Football »

US headed to Women's World Cup with 6-0 win over Jamaica


AP, Frisco :The U.S. women's national team breezed through CONCACAF qualifying to secure a spot in the World Cup next year in France.The Americans still have to face Canada."Just because we qualified for the World Cup doesn't mean we're going to take our foot off the gas," Alex Morgan said. ...

Cricket »

India ready to unleash 'fearless' Shaw, Pant on Australia


"Fearless" young batting stars Prithvi Shaw and Rishabh Pant will be India's special weapons during their upcoming tour of Australia, according to captain Virat Kohli.Hailing the roles of 18-year-old Shaw and 21-year-old Pant in the two-Test victory over the West Indies, Kohli said they had been given free rein to ...

International »

Saudi Arabia warns against any sanctions over missing Khashoggi case


Reuters, Washington :Saudi Arabia on Sunday warned against threats to punish it over last week's disappearance of journalist Jamal Khashoggi, as European leaders piled on pressure and two more US executives scrapped plans to attend a Saudi investor conference.Khashoggi, a US resident and Washington Post columnist critical of Riyadh's policies, ...

International »

Prince Harry and wife Meghan expecting a baby


AFP, London :Prince Harry and his wife Meghan, the Duchess of Sussex, are expecting a baby in the spring of 2019, they announced on Monday as they began a Pacific tour."The Royal Highnesses the Duke and Duchess of Sussex are very pleased to announce that the Duchess of Sussex is ...

Entertainment »

Ranveer-Sara soak up the Swiss Sun with Rohit Shetty


Bollywood stars Ranveer Singh and Sara Ali Khan, who are in Switzerland to shoot for their upcoming action-drama Simmba, look all geared up for the weekend and their recent picture is a proof! Taking to her Instagram, Sara shared snaps from the set in which she can be seen posing ...

City »

BNP Standing Committee Member Amir Khasru Mahmud Chowdhury speaking at a rally organised by Nagorik Adhikar Andolon Forum at the Jatiya Press Club on Monday to meet its various demands including withdrawal of false cases filed against BNP Chief Begum Khaleda Zia and her son Tarique Rahman.


Editorial »

Take seriously the promise made to the editors


The Editors' Council will form a human chain in front of the National Press Club today (Monday) to press for amendments to nine sections of the Digital Security Act. Earlier, the Council postponed the same program following an assurance from three ministers including the information minister Hasanul Haq Inu that ...

Sports »

Marcelo Melo of Brazil (left) and his partner Lukasz Kubot of Poland bite their winning trophy as they pose for photographers after beating Jamie Murray of Britain and Bruno Shares of Brazil in the men's doubles final match of the Shanghai Masters tennis tournament at Qizhong Forest Sports City Tennis Center in Shanghai, China on Sunday.


International »

Trump explains `eligibility` for those who want to come to US


PTI, Washington :US President Donald Trump has said that he wants people with merit, who can help, to enter the country and not sneak inside the border illegally."I'm very tough at the borders. We've been very tough at the borders. People have to come into our country legally, not illegally. ...

International »

US wants ‘regime change’ in Iran: Rouhani


Reuters, Tehran :The United States is seeking "regime change" in Iran, President Hassan Rouhani said on Sunday, adding that the current US administration is the most hostile that the Islamic Republic has faced in its four decades.Tensions have increased between Iran and America after US President Donald Trump withdrew from ...

City »

Former adviser to the caretaker government Dr Hossain Zillur Rahman addressing a press conference on the occasion of 4th International Health Conference of People's Health organised by People's Health Movement- Bangladesh at VIP Lounge , Jatiya Press Club yesterday.


Entertainment »

Nadia in new telefilm


Entertainment Report :After returning country popular TV actress and model Nadia Ahmed has acted in a new telefilm titled Debor, which is based on a life-oriented story. Written by Barrister Mostaq Ahmed, the telefilm is directed by Sanjay Barua. The shooting of the telefilm has already been done in the ...

Editorial »

Mysterious disappearance of Saudi journalist Khashoggi


MYSTERY shrouds the disappearance of journalist Jamal Khashoggi when Turkish authorities didn't revoke their claim that he was killed inside the Saudi Consulate in Istanbul amid strong denials by the Saudi government. The Turkish newspaper "Sabah" yesterday reported that Khashoggi may have recorded his own death by his Apple Watch. ...

Sports »

Danielle Kang of the United States reacts on the 18th hole after finishing the third round of the LPGA KEB Hana Bank Championship at Sky72 Golf Club in Incheon, South Korea on Saturday.


.

 
Items that you save may be read at any time on your computer, iPad, iPhone or Android devices.
 
Are you new to our website? Do you have already an account at our website?
Create An Account Log in here
Email this news to a friend or like someone
Email:
Write a comment to this news